Article Details
Retrieved on: 2024-02-19 13:37:53
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article from The Motley Fool suggests investing in Exelixis and Adyen, highlighting the former's oncology drug, Cabozantinib, and the latter's fintech platform. The tags reflect Exelixis's work on cancer treatments, including Zanzalintinib for colorectal cancer, and Adyen's role in fintech, competing with PayPal.
Article found on: www.theglobeandmail.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here